Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : K2 HealthVentures
Deal Size : Undisclosed
Deal Type : Financing
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
Details : The company intends to use the proceeds of the loan facility to advance the clinical development of ASLAN003, a promising candidate for the potential treatment of autoimmune gastrointestinal and skin diseases, especially inflammatory bowel disease as wel...
Product Name : ASLAN003
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2021
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : K2 HealthVentures
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors.
Product Name : ASLAN003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2021
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide.
Product Name : ASLAN003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2020
Lead Product(s) : Farudodstat
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable